cancer screening project banner
November is Lung Cancer Awareness Month

lung cancer awareness month badge The International Association for the Study of Lung Cancer (IASLC) is leading a joint effort among a consortium of non-profit lung cancer patient advocacy organizations and individuals. This effort is designed to produce a coordinated, harmonized public awareness campaign for Lung Cancer Awareness Month (LCAM) in November 2018. A critical part of this campaign is to share and widely promote the stories of lung cancer survivors, caregivers, and families of those who have been diagnosed with lung cancer. You can view these stories on the campaign's brand new website.
Lung Cancer SCREENING IS FOCUS OF COMPREHENSIVE CANCER CONTROL PROGRAM in Delaware

lung cancer image In July 2018, the Delaware Division of Public Health (DPH) released its annual report, Cancer Incidence and Mortality in Delaware, 2010-2014. The report provides data for all cancer sites combined (all-site cancer), 23 site-specific cancer types, risk factors, early detection and screening recommendations, and census tract maps.

In response to the findings, the Division of Public Health released the following statement:  "The Delaware Division of Public Health (DPH) officials acknowledge that there is still much more work to be done regarding specific cancer types. Of particular concern is lung cancer, which is the most frequently diagnosed cancer in the nation and in Delaware. Lung cancer continued to account for 14 percent of all newly diagnosed cancer cases and 30 percent of all cancer deaths in Delaware from 2010 to 2014.  In the coming year, the DPH Comprehensive Cancer Control program will focus its outreach efforts on educating consumers and providers about the importance of lung cancer screening for high-risk groups and will collaborate with the DPH Tobacco Prevention and Control program on cessation efforts and proactive policies. According to the U.S. Department of Health and Human Services, 85 percent to 90 percent of lung cancers are caused by tobacco use. Though cigarette smoking prevalence among Delaware adults was at an all-time low of 18 percent, according to the 2016 BRFS, it remains largely unchanged over the last four years."

arhq offers tools to help providers discuss lung cancer screening with patients

resource icon The Agency for Healthcare Research and Quality (ARHQ) has a variety of resources to facilitate discussions between health care professionals and their patients about lung cancer screening with low-dose computed tomography (LDCT).
acr website allows patients to locate accredited lung cancer Screening Centers

For screening to be most effective, patients must be able to access high-quality centers offering the service, such as those accredited by the American College of Radiology (ACR).

According to the American Lung Association's State of Lung Cancer report , Delaware ranked 1st among all states with 21.1 accredited lung cancer screening centers per million people, much better than the national rate of 4.8 centers per million people. There are a very high number of screening centers throughout the state available to the high-risk population in Delaware. This increases the likelihood that an individual would have access to a screening center nearby and reduces a barrier to lung cancer screening.

Use the ACR accredited facility search to help guide your patients to a screening site.
HERE ARE THE STATS ON Lung Cancer IN DELAWARE

up down icon Delaware has made progress in decreasing the incidence and mortality rate of lung cancer, but there is still much room for improvement. Some of the lung cancer findings in the incidence and mortality report are listed below:
  • Delaware ranked 10th in the nation for lung cancer incidence, the same ranking as in 2009-2013.
  • For the 2010-2014 time period, Delaware females ranked 10th highest in the nation in lung cancer mortality while Delaware males ranked 16th.
  • From 2000-2004 to 2010-2014, Delaware's lung cancer incidence rate decreased 8 percent. The national incidence rate decreased 12 percent.
  • From 2000-2004 to 2010-2014, Delaware's lung cancer mortality rate declined 14 percent. The national mortality rate declined 18 percent.
Talk to your patients who smoke or have smoked about getting a lung cancer screening

cigarette A low-dose computed tomography (LDCT) scan is recommended to detect lung cancer in individuals who have a high risk of developing lung cancer but no signs or symptoms. Studies have shown that this form of screening can detect cancer when it's most treatable - reducing the risk of dying of lung cancer.

Your patients should be screened if they:
  • Have a calculated pack years of 30 or more
    • For example:
      • Smoked a pack of cigarettes a day for 30 or more years, or
      • Two packs a day for 15 or more years
  • Currently smoke or have quit smoking within the last 15 years
  • Are between the ages of 55 and 80
You are encouraged to share this article, " For current, former smokers, this screening could save your life, " with your patients. The article was written by four members of the Delaware Cancer Consortium, Dr. Rishi Sawhney, Dr. James Spellman, Dr. Nicholas Petrelli, and Dr. Stephen Grubbs, and  urges all current and former smokers to talk with their health care provider about this lung cancer screening.
Webinar provides overview of WHAT CLINICIANS NEED TO KNOW about lung cancer screening guidelines 

webinar icon The National Lung Screening Trial  provided clear evidence of a lung cancer mortality reduction in high-risk patients who undergo screening with low-dose CT. This has changed clinical guidelines and radically influenced health care policy, for the first time offering early detection for the largest cause of cancer death. Debate continues about optimal selection criteria for screening, and minimizing the unintended harms of early detection. The institution of lung cancer screening affords the largest opportunity for cancer death reduction in a generation, yet requires thoughtful implementation with expertise in evaluation and management of screen-detected abnormalities.

The goal and purpose of this webinar is:
  • Recognize the current status of Lung Cancer Screening clinical guidelines in the United States;
  • Identify the challenges of implementing Lung Cancer Screening in clinical practice; and
  • Illustrate the evaluation and management of screen-detected abnormalities.
lung cancer on computer

learn about lung Cancer Screening with Low-Dose CT: Updates and Building a Screening Program

View an educational webinar featuring expert Christopher Lee, M.D., Associate Professor of Radiology at Keck School of Medicine of USC. Learn about the National Lung Screening Trial (NLST) results, current lung cancer screening guidelines, current reimbursement landscape, keys for building a successful lung cancer screening program, and more.
join us

Quality Insights is here to help YOUr practice improve preventive lung cancer screening rates

Quality Insights invites you to be part of a new and important Preventive Lung Cancer Screening (PLCS) quality improvement effort. We are enrolling a limited number of new practices, so act now.
 
Benefits of participation:
  • Become an industry leader for PLCS quality improvement efforts
  • Receive on-site support to improve lung cancer screening rates
  • Secure the opportunity to be highlighted as a Delaware success story to both the Delaware Division of Public Health and the Centers for Disease Control and Prevention (CDC)
Get Started Today
For more information and to receive a copy of our project agreement, please email Sarah ToborowskiYour participation in this work creates a foundation for your quality improvement efforts, as well as prepares your practice for future value-based payment models.
contact information

For more details about the Cancer Quality Improvement Project , please contact Sarah Toborowski.

Quality Insights logo      
This publication was supported by the Cooperative Agreement Number NU58DP006349-02 from the Centers for Disease Control and 
Prevention.  Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers 
for Disease  Control and Prevention. Publication number DEDPH-CS-112818